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That drugs may potentiate the harmful ef-
fects of sunlight is now a matter of common
knowledge and experience. Tins unique side
reaction to drugs has been brought emphati-
cally to the attention of clinicians largely be-
cause two widely used classes of drugs, the
phenothiazine tranquilizers and the tetracycline
antibiotics (mainly demethylchlortetracycline)
have proved to be photosensitizers. The record
to date indicates that photosensitivity is usu-
ally discovered accidentally after the drug
makes its debut into clinical practice. There is
an immediate need for pre-clinical testing pro-
cedures which will identify such drugs and
estimate their photosensitizing potentialities.
Photosensitivity includes phototoxicity arid
photoallergy. The former is distinguished by its
appearance in virtually all subjects on the very
first exposure to the appropriate doses of drug
and light. Piiotoallergy is an immunologic phe-
nomenon which requires an induction period
before sensitization is established. In this
paper, we are exclusively concerned with
phototoxic reactions which follow the oral or
parenteral use of drugs. Contact phototoxicity
after topical application will be ignored herein.
An animal screening technique is a logical
first step. Substantial progress has recently been
made. Using California sunlight, Sarns and Ep-
stein have demonstrated phototoxic reactions in
guinea pigs to demethylchlortetracycline
(DMC), chlorpromazine, and chlorothiazide
(1). Sams had considerably less success with
artificial light sources (2). Sunlight for all its
brilliance and good cheer, can scarcely be any-
thing but a vexation to the experimenter. It
varies from hour to hour, from place to place,
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and from season to season. It is often unat-
tainable in any form. Ison and Blank's' dein-
onstration of phototoxic reactions in hairless
mice exposed to long-wave ultra-violet light is
a promising development (3). They quantitated
the responses to intraperitoneally injected tet-
racyclines, phenothiazine and 8-methoxypso-
ralen; however, this system may lack high
sensitivity in that animals treated with chloro—
tlnazide and tolbutamide evidenced no photo-
toxicity when irradiated with their fluorescent
light source (General Electric F-40 BL Lamp).
We have addressed ourselves to the problem,
using human subjects, and have succeeded in
developing convenient screening techniques
based on irradiating injected or topically
treated sites with long ultraviolet light.
Baer and Harber's article should be con-
sulted for a thorough discussioi of the differ-
ences between phototoxic and photoallergic
reactions (4)
MATERIALS AND METHODS
1. Subjects. The subjects were white, adult pris-
oner-volunteers. The back served as the test site.
2. Light sources. The common light sources,
the various mercury arcs, carbon arcs, 'sunlamps',
etc. have usually been disappointing in verifying
phototoxicity. For example. Cahn and Levy could
not elicit phototoxicity to chlorpromazine with
the hot quartz lamp in the very subjects who ex-
perienced such a reaction in sunlight (5). Similarly
Schorr and Monash were unsuccessful with artifi-
cial light sources in sites injected with tetracyclines,
though sunlight was highly effective (6). Likewise,
while filtered sunlight was effective, Maibach et al
could not demonstrate phototoxicity to demethyl-
chlorotetracycline in humans with a variety of
light sources (7). Evidently, the appropriate wave
lengths are not present in sufficient intensity.
Tnitially we thought it desirable to construct a
light system whose emission would correspond to
sunlight. The model we used was basically TJrbach's
"Solar Simulator" which utilizes a high intensity
xenon lamp to produce a continuous spectrum
approximating Bener's h 600 sun (8).
In our set-up, the energy source was a 1600
Watt Osram Xenon arc powered by a Christie
Silicon Rectifier. The beam was focused on a two
inch square of skin by a quartz lens at a distance
of 60 cm. Heat was reduced by passing the beam
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through 10 cm of circulating water in which an
infra-red absorbing Corning Filter #9863 was im-
mersnd. The addition of the Schott 2 mm WG
filter provided 'solar simulation' in the ultra-
violet range. An average erythema dose is about
two minutes, the equivalent of about 20 minutes
of clear mid-day June sunlight at 40° N. L.
necessary, for exposures exceeding several minutes,(Philadelphia, Pa). Despite the heat filters it was
necessary, for exposures exceeding several minutes,
to cool the skin with a fan. We shall refer to this
as "Xenon-Solar radiation."
As it turned out, solar simulation was an un-
necessary refinement. The real value of this
system is high irradiance in the long ultraviolet,
the region which is photoactivating for practically
all known phototoxic drugs.
Other light sources were:
1. The Westinghouse FS—20 Sunlamp emitting
mainly erythemic radiation in a continuous spec-
trum between 290—310 nm.t Four fluorescent lamps
were housed in a reflector unit.
2. Westinghouse Blacklight, 320 to about 400
nm, peaking at about 360 nm, i.e. long U. V. A
hank of 4 lamps were utilized as above.
3. Filters: With sunlight or solar simulators it
seemed likely that exclusion of the erythemato—
genie rays would be advantageous. With increasing
evidence that the phototoxic action spectrum
principally lies in the long ultraviolet, the presence
of erythematogenic radiation, 290—310 nm, would
at best he superfluous and at worst an interference,
since the sunburn erythema could easily mask or
blur phototoxic erytherna. The highly effective
sunburn rays would markedly limit the dose one
could administer without creating a brilliant der-
matitis. Without the sunburn rays one could in-
crease the exposure many fold; moreover, evalua-
tion would be greatly simplified, since ervthema
itself would constitute a positive response. At 320
nm the energy required to produce erythema may
he as much as two orders of magnitude greater
than 310 nm (9, 10, 11). Hence, window glass
cutting out radiation below 320 nm usually pre-
vents sunburn even with four hours of intense
sunlight.
Experimental evidence of the masking effeet of
the sunburn rays is illustrated by Ison and Blank's
observation that chlorothiazide phototoxicity in
hairless mice could not he detected with sunlight
except through window glass (3).
In humans, whereas none of 30 DMC treated
subjects exhibited solar phototoxicity, the use of
0.005 D Mylar, a duPont plastic film which cuts
off practically all radiation below 310 nm, enabled
the detection of positive reactions in 16 to 24
subjects (7) Sams has published transmittance
curves for various thicknesses and types of Mylar
film (2). These are inexpensive and availahle in
large sheets. Sams also showed that a few hours
of ultraviolet radiation damages tile film trans—
t nm refers to nanometer. It is a billionth of a
meter, the equivalent of a millimicron.
mittance becomes less and is shifted to longer
wavelengths. In comparison to window glass, the
cut-off with Mylar films is steeper. The elicitation
of phototoxic reactions through window glass and
Mylar confirms Ippen's earlier assertion that the
action spectrum of phototoxic drugs was in the
long U. V. (12). We shall consider that long. U. V.
includes the range between the upper end of the
sunburn spectrum and the beginning of visible
radiation, namely 320 to 400 nm.
Accordingly, we have made extensive use of
Mylar films (and window glass) to eliminate
erythemic radiation. We shall call this "Xenon—
Mylar" radiation.
Drugs: Because of their phototoxin eminence
we have focused strongly on the tetracyclines and
the phenothiazines as experimental models, prin-
cipally dernethylchlortetracycline (DMC) and
ehlorpromazine. Other phototoxic drugs were:
ehlorothiazide, sulfisoxazole, sulfanilamide, griseo-
fulvin, and tolbutamide. Oral, topical, and intra—
dernml methods of administration were evaluated.
RESULTS
Oral Administration
Chlortetracycline, tetracycline HC1 de-
methylchlortetracycline (DMC), and chlor—
promazine were administered four times daily
for six days. The subjects received the follow-
ing exposures: 1) ten minutes of xenon-Mylar
radiation, 2) one MED of xenon-solar radia-
tion, 3) one MED of strictly erythematogenic
radiation obtained by inserting an interference
filter transmitting between 290 to 310 mm, and
4) one hour of black light from a bank of
four Westinghouse black lamps at a distance
of 12 inches. The exposures were made on the
sixth day, alter the morning dose, with ap-
propriate light controls. The sites were ex-
amined at 6, 24, and 48 hours. A positive re-
action consisted of ervthema.
The results are shown in Table I. Phototoxic
reactions were limited to DMC and chlor-
promazine; these were mainly elicited by
xenon-Mylar radiation. Tlus radiation gave
positwe respoimes in 13 ol 31 subjects re-
ceivirig 1200 rng of DMC daily and 9 ol 11
subjects received 800 mg of chlorpromazine.
The greater activity ol chlorpromazine cor-
relates well with clinical experience. Xenon—
solar radiation was all but ineffective; positive
responses were limited to 2 of 14 DMC treated
subjects and 4 ol 11 chlorprornazine subjects.
Strictly erythemic radiation through the inter-
ference filter was completely inactive as was
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one hour of black light. The latter result
seemed puzzling in that all the data pointed to
the long TJV as the activating radiation.
That this failure was attributable to the low
energy of the black light lamp source was
shown by increasing the exposure to two hours.
Six subjects who displayed DMC phototoxicity
to xenon-Mylar radiation were again given 1200
mg daily and retested with two hours of
black light. Positive reactions were obtained
in all six.
These results confirm that long ultraviolet
light contains the appropriate rays for photo-
toxicity. As regards chlorpromazine, our find-
ings verify Schulz, Wiskemann and Wulf's (13),
but not Epstein et al. (14). The latter impli-
cated sunburn radiation because window glass
abolished the reaction. Our findings are further
evidence that erythemic radiation is not con-
cerned in drug phototoxicity.
It does not appear that oral testing is suffi-
ciently sensitive for initial screening. The pho-
tot.oxic potentiality of chlortetracycline and
tetracycline HC1 remained completely un-
disclosed; moreover, only 4 of 26 subjects on
600 mg of DMC reacted and 2 of 8 on 400 mg
of chlorpronmzine, though the latter is no-
toriouslv troublesome in clinical practice (15).
The uncertainties inherent in oral testing are
accented by the divergent results obtained by
other investigators studying DMC. The inci-
dence in sunlight varied: none in Maibach's
series (7), 20% by Cahn, Levy, and McMillan
(16), 25% by Orentreich et al. (17), and with
high doses, about 50% by Kligman (18). Such
great differences lead one to speculate that the
quality of sunlight might be a significant factor.
Kligman did his studies in September when the
interfering erythernic radiation was low and the
longer wave lengths proportionately greater. On
the other hand, Maibach and Epstein may have
been betrayed by the famous California summer
sunshine which is so rich in erythematogenic rays.
If one wishes to usc sunlight, the best strategy
apparently is to expose the subjects at mid-day
in fall or spring, or morning or afternoon in
summer, at which times the erythernic compo-
nents are weaker and the long UV proportion-
ately greatcr.
Since completing the above studies we have
developed a simple method for increasing the
sensitivity of oral testing. This consists of
stripping the skin to the glistening layer with
Scotch Tape® just prior to light exposure. The
results of "provocative" photo patch testing
will be presented in another paper. Removal of
the horny layer greatly augments the amount
of light entering the skin. The control is an
unirradiated stripped site. Provocative testing
has markedly intensified the skin reaction in
DMC positive subjects; even more important,
positive reactions were obtained in three of five
subjects who were previously unreactive with-
out stripping.
Finally, a limited histologic study proved be
yond doubt that erythernatogenic radiation
could mask a true phototoxic response. Four
subjects received one MED of xenon-solar radi-
TABLE I
Oral pholotoxicity testing with different light sources
Drug Daily dose(mg.)
Xenon solar
radiation
(290—800 nm)
Fhck light
(320-400 nm)
Chiortetracycline
Chiortetracycline
Tetracycline HC1
Tetracycline HC1
Demethylchlortet-
racycline
Demethylchlortet-
racycline
Chlorpromazine
Chlorpromazine
Xenon-Mylar
radiation
(>310 nm)
No. subj. reactions
15 0
8 0
15 0
7 0
26 4
31 13
8 2
11 9
2000
3000
2000
4000
600
1200
400
800
Sunburn radiation
(290—310 nm)
Pos. No. subj.No. subj. reactions
15 0 15
— — S
15 0 15
5 0 5
11 0 18
14 0 14
8 0 8
10 0 11
Pos.
reactions
0
0
0
0
3
2
0
4
No. subj.
8
6
10
5
7
11
8
8
Pos.
reactions
0
0
0
0
0
0
0
0
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ation before and after taking 1200 mg of DMC
daily for 5 days. The skin was biopsied 12 hours
post irradiation. Clinically there was no ac-
centuation after dnig treatment. Histologically,
however, there was a differentiating feature,
namely a modest infiltrate with polyrnorpho-
nuclear leukocytes after the drugs. These were
completely absent in the controls. Polyrnorpho-
nuclear leukocytes are a feature of the photo-
toxic reaction in guinea pigs also (2).
mt radermal Injection
In 1939 S. Epstein confirmed the clinical
evidence of sulfanilamide photosensitivity by
irradiating sites injected with 1% solutions
(19). Each of six subjects reacted on the first
exposure. Schorr and Monash used the same
technique to reveal phototoxicity to dernethyl-
chlorotetracycline and tetracycline HC1 (6).
The simplicity of tins method is attractive.
In the following studies a volume of 0.1 ml
was injected intradermally. Pilot studies were
carried out with DMC and chlorpromazine us-
ing a series of two-fold dilutions. Physiologic
salt solution was the diluent. Control sites re-
ceived the drugs alone. Because 0.125% was
adequate while non-irritating, we elected to
carry out base line studies with this concen-
tration.
(a) Interval between injection and irradia-
tion—The backs of six white subjects were in-
jectecl intradermally with 0.125% DMC and
chlorpromazine. Separate sites were exposed to
10 minutes of xenon—Mylar at the following
times after injection: immediately, two hours,
six hours, and 24 hours.
All subjects reacted to both agents im-
mediately and at two hours; however, the two
hour responses were somewhat diminished,
particularly with DMC. This may reflect
swifter clearance from the skin as suggested by
the more rapid disappearance of the injection
'heal. By six hours only two of the DMC
treated sites reacted, as compared to four for
chlorpromazine. Only one chlorprornazine sub-
ject reacted at 25 hours.
That irradiation immediately after injection
is optimal, indeed sometimes obligatory, was
shown strikingly for chlorothiazide and sulf-
anilarnide (0.125%). Whereas each of five
subjects were positive to both agents when ir-
radiated immediately, none reacted after two
hours. We suffered many disappointments with
these and other less powerful phototoxic drugs
until this was realized. Perhaps certain drugs
are rapidly cleared or are metabolized to an
inactive form.
(b) Length of exposure—The backs of five
subjects were injected with 0.125% DMC and
chlorpromazine. Immediately each site was
exposed to xenon-Mylar irradiation for the
following periods: 3, 6, 12, and 16 minutes:
Positive reactions were obtained in almost
every instance with three minute exposures;
this is the threshold close for the reactions
were borderline positive. Six minutes gave
sharp responses; these were not appreciably
intensified by lengthening the exposure to 12
and 16 minutes. Clearly, the light dosage re-
sponse curve is very shallow. Severe reactions
cannot be induced by almost tripling the ex-
posure. We adopted the 6 minute exposure for
routine use; this contains an amount of long
IJ.V. equivalent to about one hour of summer
sunlight in our latitude.
(c) Evolution of the phototoxic reaction.—
It was necessary to obtain data which would
indicate the optimal time for reading the re-
actions. The evolution of the sunburn and pho—
totoxic reactions was clearly different. The
backs of five subjects were injected with 0.125%
concentrations of DMC and chlorpromazine and
exposed to six minutes of xenon-Myler radia-
tion. Each subject was continuously observed
for six hours, again at 12 hours, and finally at
24 hours. The size of the edema and the
erytherna were recorded. In each instance, the
irradiated site began to react almost immedi-
ately after exposure, indicated mainly by a
spreading edema greater than the injection
wheal of the control site. After about 20—30
minutes the edematous papule began to ex-
hibit erythenm; the peak was usually at-
tained by one to two hours. The wheal of in-
jection had generally become negligible by two
hours. The reaction consisted of a central area
of firm edema surrounded by an ervthernatous
halo of variable dimensions. With DMC, both
the ervthema and swelling had diminished
somewhat by six hours while the chiorproma-
zine response was still near peak. Although the
reactions were usually positive by 24 hours,
they had become borderline in quality, es-
pecially with DMC. Seeking confirmation of
the desirability of reading the sites at two
hours, we injected three individuals with
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TABLE II
Minimum phototoxic concentrations after
intradermal injection
Drug MPD (%Y
Demethyichiortetracycline 0.0016
Chiortetracycline 0.031
Tetracycline HC1 0.031
Methacycline HC1 Non-phototoxic
Minocycline Non-phototoxic
Chiorothiazide 0.125
Chiorpromazine 0.0004
Promethazine 0.0008
Sulflsoxizole 0.125
Sulfanilamide 0.125
Griseofulvin 0.125
Tolbutamide 0.063
* The MPD is the least concentration giving a
positive reaction in 3 of 4 subjects.
0.125% concentrations of chiorothiazide, sulfa—
nilarnide, griseofulvin and tolbutamide. Again
the peak was reached in about two hours
though the reaction evolved more slowly with
the last two agents. The necessity of early
reading was clearly demonstrated when thresh-
old quantities of these drugs were injected.
Quite often the sites were positive at two and
six hours and were completely negative at 24
hours.
It is clinically appreciated that phototoxic
reactions tend to emerge more rapidly and
peak earlier than ordinary sunburn.4 This was
consistently borne out in this investigation. We
adopted the convention of reading the irradi-
ated sites at two and six hours. It should be
noted that the psoralens are an exception in
that the peak is not attained for two to three
days.
(ci) Specificity of the reaction—To be re-
liable, a screening test must have high spec-
ificitv. It should register neither false positive
nor false negative reactions. It must identify
known phototoxic agents and exclude those
which are not. We have obtained no false
negative reactions with known phototoxic drugs
(Table II) tins indicates lugh sensitivity. To
evaluate the likelihood of false-positive reac-
tions we injected, in 6 subjects each, 0.125%
concentrations of the following agents, none of
which are implicated in phototoxicity (in-
soluble drugs were finely pulverized in a mortar
and homogenized in a solution containing 0.1%
Triton X-100, a nonionic surfactant) chloro-
mycetin, neomycin, testosterone propionate,
acetylsalicylic acid, ethinyl estradiol, butazoli-
dine, streptomycin, nickel sulfate, and oleic acid.
No phototoxic reactions occurred. Several
produced an inflammatory irritant response
which was not intensified by the radiation.
Thus in our experience to date neither false
positive nor false negative reactions have been
encountered.
(e) Minimum phototoxic doses—Our objec-
tive in this section was to assess comparative
phototoxic potency. We have arbitrarily desig-
nated the minimum phototoxic dose (MPD)
to be the least concentration which gives a
positive reaction in three of four subjects. In
this pilot study, we wished only to gain a
rough idea of the differences among well known
phototoxic drugs. A series of two-fold dilutions
were intradermally injected beginning with
0.125% and the sites immediately exposed to
six minutes of xenon-Mylar radiation. Insoluble
materials (griseofulvin and tolbutarnide) were
suspended in 0.1% Triton X-100. The results
are shown in Table II.
Among the tetracyclines, DMC was the most
phototoxic while the newest marketed mem-
ber, methacycline (6-dioxytetra cycline) seemed
to lack phototoxicity altogether. Minocycline
(7- dirnethylamiiio- 6- deoxy- 6- dernethyltetracy-
dine) a drug currently under investigation by
Lederle Laboratories was also non-phototoxic
by this test. In relation to DMC, the potencies
of chlortetracycline and tetracycline HC1 were
much higher than was anticipated from clinical
experience, differing only by one dilution. In-
stances of phototoxicity to these latter tetra—
cyclines are documented beyond challenge but
are distinctly rare (20, 21, 22, 23, 24, 25,
26, 27). Neither we nor Maibach et al. (7)
could demonstrate phototoxicity to these agents
after oral administration, in our case even after
three times the conventional dose. Clearly, in-
tradermal testing is unreliable for comparing
phototoxic capabilities in clinical usage. A posi-
tive intradermal test merely indicates that
the drug has the potentiality of being photo-
toxic. It certainly does not prognosticate the
probability of clinical phototoxicity. Oral or
parenteral testing is necessary to determine
whether the incidence of phototoxicity is likely
to be forbidding.
It is noteworthy that chlorothiazide and
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tolbutamide were identified as phototoxic
agents. Neither agent was active in the hairless
mouse using artificial light (3).
The MPT's of the phenothiazines were
lower than DMC by one to two dilutions. This
accords with clinical experience and with the
results of oral testing given above.
The phototoxicity of griseofulvin and two
sulfonamides, sulfanilarnide and sulfisoxizole,
was confirmed (28).
(f) Subjects. We compared the reactions to
0.125% DIVIC and chlorpromazine in whites,
light negroes, and deeply pigmented negroes,
using 5 subjects in each class. In no instance
was a phototoxic reaction observed in a deeply
pigmented negro. The responses in white and
light negroes were comparable. It must not be
assumed that deep pigmentation provides com-
plete protection; clinical experience indicates
that this happens occasionally if drug and light
exposure are prolonged. While light negroes
can be satisfactorily used as subjects, one
should not be confused by the immediate
darkening reaction which involves the oxida-
tion of melanin unaccompanied by erytherna.
As a rule the reactions are most intense in fair
skinned persons of high sunburn sensitivity, i.e.
with low MED's.
Topical Application
Schulz and his co-workers demonstrated
chlorpromazine phototoxicity by the ultimately
simple technique of topical application. A 5%
concentration was applied to the skin for 24
hours prior to irradiation.
Our interest in this technique was con-
siderably dampened when sites treated with
10% DMC in petrolatum for 24 hours failed to
react. Tins was also the experience of Harber et
al. (29). Two developments rekindled our interest
in topical testing: 1) twenty four hour applica-
tions were found to be too long, 2) Scotch Tape®
stripping (provocative test) immensely en-
hanced the effectiveness of the test.
Ten percent concentrations of the above
phototoxic agents were made up in petrolatum
awl applied to both normal and stripped skin
for one and 24 hour periods under an occlusive
dressing of impermeable tape in accordance
with the standard technique we use for patch
testing in contact allergy (30). Each site re-
ceived six minutes of xenon-Mylar radiation
after one and 24 hours. The control was un-
Drug No. subj.
Positive reactions
Normal skin
1 hr. 24 hrs.
Stripped skin
1 hr. 24 hrs.
DemethykMor-
tetracycline
Chorpromazine
Promethazine
Sull'anflamide
Griseofifivin
Tolbutamide
Clilorothiazide
6
5
4
4
4
4
4
4
5
4
4
0
0
3
0
5
4
4
0
0
4
6
5
4
4
4
4
4
Q
5
4
4
4
4
4
irradiated, drug treated stripped skin. The re-
sults are shown in Table III.
The salient finding was that every subject
reacted to every drug after one hour applica-
tion to stripped skin (Table III). The value of
stripping as a provocative test was vividly
demonstrated with griseofulvin and tolbutarnide
neither of which were photopositive on un-
stripped skin. These agents probably do not
penetrate the horny layer barrier. Perhaps this
is why griseofulvin is inactive topically against
ringworm infection. It is not possible to ex-
plain why 24 hours is so much inferior to one
hour in the case of DMC.
Further experience has increased our con-
fidence in topical testing. Positive reactions
could generally be elicited evei after a few
minutes of application to stripped skin. Thirty
minute applications were just as effective as one
hour. With high concentrations (10%) any
vehicle can be used including the common
emulsion creams, Carbowax® TJ.S.P. lanolin or
cven water. The site should be thoroughly
wiped with gauze before irradiation to remove
excess drug. In many instances 1% concentra-
tions were adcquate to reveal phototoxicity in
stripped skin but the reactions were definitely
weaker. The reactions evolve more slowly
than by the injection technique, reaching a
peak at four to eight hours. This is perhaps not
the ideal time for evaluation, however, since
the trauma of stripping is still conspicuous.
The difference between a phototoxic response
and the unirradiated stripped-drug control is
generally clearer at 24 hours.
TABLE III
Photoloxic responses on normal and stripped skin.
treated with 10% concentrations of the drugs for
1 and 24 hours before irradiation
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TABLE IV
Comparison of different wavelengths in photoactivating sites injected with 0.125% concentrations of the drugs
Drug No. of subj.
5
5
S
Positive reactions
.005 D Mylar Window glass(>SlOnm) I (>320nm)
Schott WG 1 Boo D weatherableMylar(>350nm) (>400nm)
Minutes
1 2
0 2
1 401
3
5
5
5
1
0
1
0
2
1
3
2
3
5
5
5
1
0
1
0
2
0
3
1
3
5
5
5
16
2
2
1
18
5
5
3
20
5
5
5
Demethylclilortet-
racycline
Chiorpromazine
Sulfanilamide
The topical method is appealingly simple
and gives much promise for preliminary screen-
ing.
Action Spectra
The action spectrum is defined by the wave-
lengths of light that incite the phototoxic re-
sponse. It is worth emphasizing that it is not a
single point but a range which generally has a
peak or span of highest effectiveness. Persons
unfamiliar with this subject are usually puzzled
to learn that the absorption spectrum, de-
termined in vitro, does not necessarily cor-
respond to the in vivo action spectrum. For
example, chlorpromazine has practically no
absorption in the long UV though this is the
photoactivating range (2). Likewise, there is
no correspondence between the action and
absorption spectra of the furocoumarins (31).
This disparity does not negate the Grotthus-
Draper principle which asserts that there call-
not be a photochemical reaction unless radia-
tion is absorbed. Though one cannot yet
provide a conclusive explanation, it is very
1ikey that the native chemical is not the pho-
tosensitizer but becomes so after metabolic
transformation or by cornpJexing with some
critical material such as DNA.
Precise delineation of the action spectrum
requires a rnonochromator. To our knowledge,
only a single phototoxic drug, 8-methoxypsora-
len, has been thoroughly studied in this way.
Maximal activity lies between 320 and 370
nm with a probable peak at 360 nm, again in
the long liT (31). Lacking a mono chromator
one can roughly establish the photoactivating
range by using filters which successively cut
off portions of the continuous spectrum. Ac-
cordingly, we determined the minimal times
necessary to elicit reactions with the following
filters in the xenon system:
1. 0.005 D Mylar, cut-off at about 310 urn.
2. Window glass, cut-off below 320 nm.
3. Schott 3 mm, WGI filter, cut-off about 350
nm.
4. 500 D 'weatherable' Mylar, cut-off at
about 400 nm; i.e. visible radiation.
DMC, sulfanilamide, and chlorpromazine
were injected in 0.125% concentrations in five
subjects each and the sites immediately irradi-
ated. The results are given in Table IV.
Window glass did not weaken the reaction
at all. Neither did the WOT filter appear to
depress the response. Evidently radiation be-
low 350 nm is of little importance. On the other
hand, radiation beyond 400 nm into the visible
range, is still capable of activating the reac-
tion though much less efficiently since the ex-
posure had to be increased by a factor of
about six, approximately 18 minutes instead of
three. These observations, unequivocally dem-
onstrate that the photoactivating rays lie
chiefly in the long CV with some extension
into the visible range.
Our results conflict with Sams and Epstein's
findings in guinea pigs with sunlight; they
fouiid that window glass diminished the pho-
totoxic reactions to DMC and chlorpromazine
(1). Clinically, there are undoubted instances
of phototoxicity through window glass affecting
individuals sitting indoors or riding in auto-
mobiles (20, 21, 22). Magnus has adapted the
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intradermal technique to hairless mice and has
determined the action spectra for DMC and
sulfanilamide with his monochromator. The ac-
tion spectrum for DMC extended from 350 to
420 nrn with a peak at 400. For sulfanilamide
the principal range was 375 to 400 nm. Lesser
activity was noted at 280 to 320 nm and 550
to 600 nm (personal communication). This
agrees splendidly with our far cruder measure-
ments. The major action spectrum for all
known pliototoxic drugs appears to lie in the
long UV. It is worth reiterating that even
visible light can active phototoxicity. Schulz et
ol. also demonstrated chlorpromazine photo-
toxicity with radiation above 420 nm (13).
DISCUSSION
These studies indicate the feasibility of using
locally treated and irradiated skin as a screen-
ing technique for identifying phototoxic agents.
The criterion of specificity has apparently been
satisfied; phototoxicity can only be elicited
with drugs that have been so stigmatized
clinically. Many agents can be tested on the
same subject.
An important qualification of local testing is
that quatititative estimates of potency do not
correspond to the results obtained with sys-
ternic administration. A positive result only
signifies phototoxic potentiality, not clinical
actuality. The tetracyclines furnish a convinc-
ing illustration of this. Chiortetracycline and
tetracycline HC1 rarely cause phototoxic re-
actions; yet their intradermal potency is only
slightly less than the potent clinical photo-
sensitizer, DMC. If local testing reveals pho-
totoxic potentiality, one is obliged to administer
various doses of the drug orally or parenterally
followed by irradiation of stripped sites. Sys-
temic testing enables an educated guess of the
likelihood of phototoxic reactions in clinical use.
For example, a potent phototoxic agent such
as dernethylchlortetracycline was readily iden-
tified hut its congeners, chlortetracycline and
tetracycline, were completely ineffective even
with two to three times the normal dose. Thus,
the combination of topical phototoxicity and
inactivity systemically prophesizes that the
clinical reaction rate will probably not be pro-
hibitive. The results suggest that oral testing
will provide a reliable basis for comparing the
phototoxic potency of different drugs. For in-
stance, chlorpromazine was found to be more
potent than DMC, a finding which corroborates
clinical experience.
Our light equipment is too expensive and too
complex for routine use. Fortunately there are
feasible alternatives. Since the action spectrum
for phototoxicity lies in the long ultraviolet,
the quartz-iodine tungsten lamp may be satis—
factorily adapted to this use. Berger (personal
communication) of the Temple University
Department of Dermatology has constructed a
simple model which will probably be available
shortly. It is much cheaper than the xenon
assembly and has such high irradiance in the
long [V that the exposures are no greater. In-
deed, six minutes with the quartz-iodine timg—
sten lamp has been completely effective in deni—
onstrating phototoxicity to all of the test drugs.
Less satisfactory but equally effective are the
fluorescent black lamps; a bank of 4, twelve
inches from the skin, will invariably elicit pho—
totoxicity with all of the agents reported herein.
The chief disadvantage is that the exposure
time must be two hours.
Specifications for Testing Pliototoxic Agents
The following description offers a tentative
guideline for the routine pliototoxic screening
of new drugs. The backs of adult white sub-
jects are utilized as test sites.
1. Topical testing is the initial step. Five
test subjects are more than adequate. The
agent is incorporated in petrolatum in 10 per
cent concentration. Lesser concentrations may
be necessary if the drug is highly irritating.
This is applied ocelusively to freshly stripped
sites for 30 minutes. The site is gauze wiped
and immediately exposed to the equivalent of
about one hour of mid-day summer sunlight
with erythemic radiation filtered out by win-
dow glass. The sites are evaluated at 24 hours.
The control is an unirradiated, drug treated,
stripped site. A reaction clearly greater than the
control indicates phototoxic potentiality.
2. Intradermal testing will usually be super-
fluous but may be used for confirmation.
The initial concentration should be 0.125%
in saline. Insoluble agents should be ground
finely and homogenized in saline containing
0.1% Triton X-100. A volume of 0.1 ml is in-
jected intradermally and immediately exposed
to long UV. The control is an unirradiated
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drug injection. The sites are read at. two hours
and again at six hours, although the latter will
usually be unnecessary.
3. Oral (or pareifteral) testing is utilized to
gain an idea of the likelihood of phototoxicity
under actual conditions of use. A positive
topical or intradermal test certainly does not
exclude the clinical use of the drug. Panels of
ten subjects are adequate; the doses should
vary from the normal to two or three times the
standard quantity. The agents should be given
for a minimum of 5 days; we have obtained
positive reactions to DMC and chlorpromazine
in as little as two days but some persons were
negative who became positive after 5 days.
Both normal aid stripped sites should be ir-
radiated with the standard dose of long UV
Readings are made at six aid 24 hours.
SUMMARY
1. Topical application and intraderinal in-
jection of human skin has been shown to be a
useful screening procedure for identifying drugs
with the potentiality of causing phototoxic re-
actions.
2. The method has high sensitivity and ap-
parently gives neither false positive nor false
negative reactions.
3. Reactions by intradermal aid topical
testing were demoistrated for the following
known phototoxic agents: 1) tetracyclines,
notably demethylchlortetracycline, 2) pheno-
thiazines, 3) chlorothiazide, 4) sulfanilarnide, 5)
sulfisoxazole, 6) tolbutamide, and 7) griseo-
fulvin.
4. The action spectrum of all these agents
lies principally in the long UN. beyond 350
nm, extending somewhat into the visible re-
gion. The light source may be either a xenon
lamp with erythernic radiation filtered out by
window glass, the quartz-iodine tungsten lamp,
or ordinary black lamps. The exposure should
be equivalent to about one hour of mid-day,
summer sunlight.
5. Tentative specifications are given for a
routine screening program including oral test-
ing to enable an estimate of the likelihood of
phototoxic reactions in clinical use.
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